Delving into the Latest Updates on Ppc China Corp. Ltd. with Synapse

Overview

Tags

Digestive System Disorders

Infectious Diseases

Therapeutic vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Infectious Diseases	2

Top 5 Drug Type	Count

Therapeutic vaccine	2

主要目的是评估imsidolimab在参与ANB019-301研究的GPP受试者中的长期安全性。次要目的是评估imsidolimab在参与ANB019-301研究的GPP受试者中的长期疗效。探索性目的是评估imsidolimab在GPP受试者中的PK；评估imsidolimab的免疫原性；进行药物遗传学分析；在ANB019-301研究第1天并发斑块型银屑病的受试者中评估imsidolimab对斑块型银屑病的影响。

[Translation]

The primary objective is to evaluate the long-term safety of imsidolimab in GPP subjects participating in the ANB019-301 study. The secondary objective is to evaluate the long-term efficacy of imsidolimab in GPP subjects participating in the ANB019-301 study. The exploratory objectives are to evaluate the PK of imsidolimab in GPP subjects; evaluate the immunogenicity of imsidolimab; perform pharmacogenetic analysis; and evaluate the effect of imsidolimab on plaque psoriasis in subjects with concurrent plaque psoriasis on Day 1 of the ANB019-301 study.

Start Date-

Sponsor / Collaborator

Patheon Manufacturing Services LLC

[+2]

100 Clinical Results associated with Ppc China Corp. Ltd.

Login to view more data

0 Patents (Medical) associated with Ppc China Corp. Ltd.

Login to view more data

100 Deals associated with Ppc China Corp. Ltd.

Login to view more data

100 Translational Medicine associated with Ppc China Corp. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 21 Mar 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

2

IND Approval

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Tetrodotoxin ( Nav1.1 x Nav1.2 x Nav1.5 )	Neuralgia More	IND Approval
Domvanalimab biosimilar(PPC China) ( TIGIT )	Non-Small Cell Lung Cancer More	IND Approval
ChAdOx1-HBV	Hepatitis B More	IND Application
MVA-HBV(Vaccitech)	Hepatitis B More	IND Application
Resigratinib ( FGFR2 x FGFR3 )	FGFR3 Mutant Neoplasms More	Discontinued